UP!
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q4 2022 | 2022-11-21 | Future report Set alerts | |
| Q3 2022 | 2022-08-08 | -1.53 | -1.53 |
| Q2 2022 | 2022-05-09 | -1.63 | -1.63 |
| Q1 2022 | 2022-02-08 | -1.48 | -1.48 |
| Q4 2021 | 2021-11-22 | -1.22 | -1.22 |
| Q3 2021 | 2021-08-05 | -1.19 | -1.19 |
| Q2 2021 | 2021-05-06 | 0.00 | 0.00 |
| Q1 2021 | 2021-02-08 | -0.41 | -0.41 |
| Q4 2020 | 2020-11-23 | -1.46 | -1.46 |
| Q3 2020 | 2020-08-04 | -0.71 | -0.71 |
| 2016-04-28 | Downgrade | JMP Securities | Outperform to Market Perform | |
| 2016-02-09 | Lower Price Target | JPMorgan Chase & Co. | Overweight | $45.00 to $38.00 |
| 2016-02-09 | Boost Price Target | Barclays | Underweight | $16.00 to $18.00 |
| 2016-02-09 | Reiterated Rating | Robert W. Baird | Neutral | $36.00 to $22.00 |
| 2016-02-09 | Boost Price Target | Barclays PLC | Underweight | $16.00 to $18.00 |
| 2015-11-24 | Lower Price Target | Robert W. Baird | Neutral | $41.00 to $36.00 |
| 2015-11-24 | Lower Price Target | JPMorgan Chase & Co. | Overweight | $54.00 to $45.00 |
| 2015-10-23 | Upgrade | JMP Securities | Market Perform to Outperform | $32.00 |
| 2015-10-23 | Downgrade | Barclays | Equal Weight to Underweight | $45.00 to $16.00 |
| 2015-08-07 | Boost Price Target | Barclays | Equal Weight | $35.00 to $45.00 |
| 2015-05-08 | Lower Price Target | Leerink Swann | Outperform | $42.00 to $41.00 |
| 2015-04-06 | Initiated Coverage | Deutsche Bank | Buy | $42.00 to $42.00 |
| 2015-04-06 | Initiated Coverage | Deutsche Bank AG | Buy | $42.00 to $42.00 |
| 2015-03-03 | Initiated Coverage | Barclays | Equal Weight | $35.00 |
| 2015-02-06 | Lower Price Target | JPMorgan Chase & Co. | Overweight | $53.00 to $47.00 |
| 2014-11-24 | Reiterated Rating | FBR & Co. | Outperform | $50.00 |
| 2014-11-24 | Reiterated Rating | FBR & Co | Outperform | $50.00 |
| 2014-10-21 | Reiterated Rating | FBR & Co. | Outperform | $52.00 to $50.00 |
| 2014-08-15 | Boost Price Target | Credit Suisse | Outperform | $43.00 to $44.00 |
| 2014-08-15 | Boost Price Target | Credit Suisse Group AG | Outperform | $43.00 to $44.00 |
| 2014-08-14 | Initiated Coverage | FBR & Co. | Outperform | $52.00 |
| 2014-07-07 | Downgrade | JMP Securities | Outperform to Market Perform | |
| 2014-06-24 | Downgrade | Robert W. Baird | Outperform to Neutral | $41.00 |
| 2014-03-10 | Boost Price Target | Leerink Swann | $29.00 to $45.00 | |
| 2014-02-18 | Boost Price Target | JMP Securities | Outperform | $50.00 |
| 2014-02-10 | Boost Price Target | Credit Suisse | $36.00 to $43.00 | |
| 2014-01-27 | Initiated Coverage | Robert W. Baird | Outperform | $41.00 |
| 2016-04-28 | Downgrade | JMP Securities | Outperform to Market Perform | |
| 2016-02-09 | Lower Price Target | JPMorgan Chase & Co. | Overweight | $45.00 to $38.00 |
| 2016-02-09 | Boost Price Target | Barclays | Underweight | $16.00 to $18.00 |
| 2016-02-09 | Reiterated Rating | Robert W. Baird | Neutral | $36.00 to $22.00 |
| 2016-02-09 | Boost Price Target | Barclays PLC | Underweight | $16.00 to $18.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In ENTA 131 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BlackRock Inc. | 3.62M |
| ARMISTICE CAPITAL, LLC | 2.07M |
| FARALLON CAPITAL MANAGEMENT LLC | 1.55M |
| Vanguard Group, Inc | 1.48M |
| BlackRock Fund Advisors | 1.45M |
| STATE STREET CORP | 1.38M |
| Apex Capital Management | 1.29M |
| NORTHERN TRUST CORP | 0.96M |
| RA CAPITAL MANAGEMENT, LLC | 0.90M |
| Krensavage Asset Management, LLC | 0.59M |
| DIMENSIONAL FUND ADVISORS LP | 0.51M |
| RENAISSANCE TECHNOLOGIES LLC | 0.47M |
| BlackRock Institutional Trust Company, N.A. | 0.46M |
| GEODE CAPITAL MANAGEMENT, LLC | 0.36M |
| Invesco Ltd. | 0.36M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| SHIONOGI & CO LTD | 8.61% (1599760) | ENTA / |
| SCHUHSLER HELMUT | 8.46% (1572670) | CNCE / ENTA / |
| SAINTS CAPITAL GRANITE, L.P. | 7.67% (1425708) | ENTA / |
| TVM V LIFE SCIENCE VENTURES GMBH & CO KG | 6.16% (1144932) | BLUE / ENTA / |
| Luly Jay R. President and CEO | 3.51% (653026) | ENTA / |
| Goldberg Marc E. | 2.95% (547606) | ENTA / |
| Or Yat Sun Chief Scientific Officer | 1.67% (309920) | ENTA / |
| MELLETT PAUL J Treasurer and CFO | 0.48% (88458) | ENTA / |
| AFTING ERNST-GUENTER | 0.09% (17287) | ENTA / SQNM / SRNE / |
| Vance Terry | 0.08% (15295) | ENTA / |
| Gardiner Nathaniel S. Sr. VP & General Counsel | 0.07% (12327) | ENTA / |
| Ocain Tim Senior Vice President | 0.03% (6127) | ENTA / |
| Adda Nathalie Sr. VP & Chief Medical Officer | 0.03% (6000) | ENTA / |
| Verdine Gregory L. | 0.02% (3324) | ENTA / |
| Buckley Stephen Jr. | 0.01% (2000) | ENTA / TKAI / |
UM